L. Faivre

发表

Outcome According to Elective Pelvic Radiation Therapy in Patients With High-Risk Localized Prostate Cancer: A Secondary Analysis of the GETUG 12 Phase 3 Randomized Trial.

S. Culine, N. Salem, M. Baciuchka, 2016, International journal of radiation oncology, biology, physics.

Outcomes and prognostic factors for relapsed or refractory lymphoma patients in phase I clinical trials

X. Paoletti, J. Soria, V. Ribrag, 2018, Investigational New Drugs.

Prognostic value of HLA-A2 status in advanced non-small cell lung cancer patients.

J. Pignon, D. Planchard, N. Chaput, 2017, Lung cancer.

Prognostic factors and outcome of patients with hematological malignancies in phase I trials: the Gustave Roussy scoring system

J. Soria, S. de Botton, V. Ribrag, 2014, Anti-cancer drugs.

Crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Preliminary results of the ACSé phase II trial.

G. Ferretti, S. Lantuejoul, G. Vassal, 2015 .

Randomized trial comparing two methods of re-irradiation after salvage surgery in head and neck squamous cell carcinoma: Once daily split-course radiotherapy with concomitant chemotherapy or twice daily radiotherapy with cetuximab.

J. Bourhis, F. Janot, A. Laprie, 2018, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

New dosing nomogram and population pharmacokinetic model for young and very young children receiving busulfan for hematopoietic stem cell transplantation conditioning

S. Broutin, O. Mir, A. Paci, 2020, Pediatric blood & cancer.

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

J. Pignon, J. Soria, B. Besse, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

TPF induction chemotherapy increases PD-L1 expression in tumour cells and immune cells in head and neck squamous cell carcinoma

J. Adam, J. Soria, O. Casiraghi, 2018, ESMO Open.

Phase I study of temsirolimus in combination with cetuximab in patients with advanced solid tumours.

A. Paci, J. Adam, J. Soria, 2017, European journal of cancer.

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial.

A. Ravaud, S. Culine, G. Deplanque, 2015, The Lancet. Oncology.

LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value.

Jordi Remon, J. Pignon, D. Planchard, 2017, Lung cancer.

Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?

J. Pignon, D. Planchard, J. Soria, 2014, Lung cancer.

Study of Intrapatient Variability and Reproducibility of Quantitative Tumor Perfusion Parameters Evaluated With Dynamic Contrast-Enhanced Ultrasonography

B. Asselain, S. Koscielny, N. Lassau, 2017, Investigative radiology.

Docetaxel-estramustine in localized high-risk prostate cancer: Results of the French Genitourinary Tumor Group GETUG 12 phase III trial.

S. Culine, G. Gravis, Anne-Laure Martin, 2014 .

Very long-term complete remission can be achieved in men with high-risk localized prostate cancer and a very high PSA value: an analysis of the GETUG 12 Phase 3 trial

S. Culine, D. Drubay, G. Deplanque, 2023, Clinical Genitourinary Cancer.

Phase I trial of everolimus in combination with thoracic radiotherapy in non-small-cell lung cancer.

J. Pignon, J. Soria, B. Besse, 2015 .

Abstract 2250: STK11 mutations in non-small cell lung cancer (NSCLC): descriptive analysis and prognostic significance

J. Pignon, D. Planchard, J. Soria, 2016 .

PACSA: Phase II study of pazopanib in patients with progressive recurrent or metastatic (R/M) salivary gland carcinoma (SGC).

F. Bidault, C. Borel, V. Costes, 2016 .

Crizotinib in children and adolescents with advanced ROS1, MET, or ALK-rearranged cancer: Results of the AcSé phase II trial.

B. Geoerger, G. Vassal, M. Jimenez, 2016 .

Impact of tumor burden on tyrosine kinase inhibitors (TKI) efficacy in advanced non-small cell lung cancer (NSCLC) patients with EGFR-sensitizing mutations (EGFRm) and ALK rearrangement (ALK+).

J. Soria, C. Caramella, B. Besse, 2014 .